-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4

Benzinga·09/23/2026 12:49:05
Citizens analyst Reni J. Benjamin maintains Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and lowers the price target from $10 to $4.